Kintara Therapeutics (KTRA) has released an update.
Kintara Therapeutics announced a reverse stock split at a 1-for-35 ratio, set to take effect on October 18, 2024, as part of its merger with TuHURA Biosciences. The move will reduce the number of outstanding shares significantly, impacting stockholders uniformly without altering their equity interests. The merged entity will trade under the new name TuHURA Biosciences, Inc. with the symbol ‘HURA’ on Nasdaq.
For further insights into KTRA stock, check out TipRanks’ Stock Analysis page.
